Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 9
Submit an article Journal homepage
833
Views
29
CrossRef citations to date
0
Altmetric
Original Articles

Venetoclax is safe and efficacious in relapsed/refractory AML

Chezi GanzelDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; ;Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-1722-4807
ORCID Icon,
Ron RamDepartment of Hematology, Tel Aviv (Sourasky) Medical Center and Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
,
Alexander GuralDepartment of Hematology, Hadassah Medical Center, Jerusalem, Israel;
,
Ofir WolachInstitute of Hematology, Rabin Medical Center, Petah Tikva, Israel;
,
Sharon Gino-MoorHematology Unit, Bnai-Zion Medical Center, Haifa, Israel;
,
Vladimir VainsteinDepartment of Hematology, Hadassah Medical Center, Jerusalem, Israel;
,
Boaz NachmiasDepartment of Hematology, Hadassah Medical Center, Jerusalem, Israel;
,
Arie ApelDepartment of Hematology, Assaf Harofeh Medical Center, Tzrifin, Israel;
,
Maya Koren-MichowitzDepartment of Hematology, Assaf Harofeh Medical Center, Tzrifin, Israel; ORCID Iconhttp://orcid.org/0000-0002-7223-328X
ORCID Icon,
Oren PasvolskyInstitute of Hematology, Rabin Medical Center, Petah Tikva, Israel;
,
Ronit YerushalmiDivision of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel;
,
Ivetta DanyleskoDivision of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel;
,
Yosef CohenDepartment of Hematology, Laniado Medical Center, Netanya, Israel;
,
Galit PeretzDepartment of Hematology, Soroka Medical Center, Beer Sheva, Israel;
,
Yakir MosheDepartment of Hematology, Tel Aviv (Sourasky) Medical Center and Sackler faculty of Medicine, Tel Aviv University, Tel Aviv, Israel;
,
Miri ZektserDepartment of Hematology, Soroka Medical Center, Beer Sheva, Israel;
,
Shay YeganehThe Baruch Padeh Medical Center, Poriya, Tiberias, Israel;
,
Jacob M. RoweDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; ;Department of Hematology, Rambam Healthcare Campus, Haifa, Israel
&
Yishai OfranDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel; ORCID Iconhttp://orcid.org/0000-0002-5521-1337
ORCID Icon show all
Pages 2221-2225 | Received 06 Nov 2019, Accepted 19 Apr 2020, Published online: 18 May 2020

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Xiaotong Chen, Yanqiu Zhao, Qi Li & Shengjin Fan. (2023) Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML. OncoTargets and Therapy 16, pages 409-419.
Read now
Andrés Gómez-De León, Roberta Demichelis-Gómez, Alfredo Pinedo-Rodríguez, Daniel Enriquez-Vera, Juan Antonio Flores-Jiménez, Adrián Alejandro Ceballos-López, Margarita Rodríguez-Mejorada, Miguel Angel Herrera Riojas, Roberto Ovilla-Martínez, Pamela Báez-Islas, Xóchitl Cota-Rangel, Yvette Neme-Yunes, Sergio Inclán-Alarcón, Nelson J. López-Flores, Perla R. Colunga-Pedraza, Anna C. Rodríguez-Zúñiga & David Gómez-Almaguer. (2022) Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America. Hematology 27:1, pages 249-257.
Read now
Molly E. Graveno, Alison Carulli, Craig W. Freyer, Brendan L. Mangan, Robert Nietupski, Alison W. Loren, Noelle V. Frey, David L. Porter, Saar I. Gill, Elizabeth O. Hexner, Selina M. Luger, Mary Ellen Martin, Shannon R. McCurdy, Alexander E. Perl, Daria V. Babushok & Keith W. Pratz. (2022) Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia. Leukemia & Lymphoma 63:7, pages 1645-1650.
Read now
Juan Tong, Na Zhao, Xing Hu, Wen Yao, Yaxin Cheng, Li Zhou, Huilan Liu, Liangquan Geng, Zimin Sun & Changcheng Zheng. (2021) Efficacy of Venetoclax Combined with Decitabine-Based Treatment for Heavily Pre-Treated Relapsed or Refractory AML Patients in a Real-World Setting. Cancer Management and Research 13, pages 5613-5621.
Read now
Jan Philipp Bewersdorf, Andriy Derkach, Lohith Gowda, Kamal Menghrajani, Susan DeWolf, Josel D. Ruiz, Doris M. Ponce, Brian C. Shaffer, Roni Tamari, James W. Young, Ann A. Jakubowski, Boglarka Gyurkocza, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. King, Sheng F. Cai, Anthony Daniyan, Christopher Famulare, Bernadette M. Cuello, Nikolai A. Podoltsev, Mikhail Roshal, Sergio Giralt, Miguel-Angel Perales, Stuart Seropian, Christina Cho, Amer M. Zeidan, Thomas Prebet, Eytan M. Stein, Martin S. Tallman, Aaron D. Goldberg & Maximilian Stahl. (2021) Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leukemia & Lymphoma 62:14, pages 3394-3401.
Read now
Jayastu Senapati, Rishi Dhawan, Mukul Aggarwal, Pradeep Kumar, Ganesh Kumar Vishwanathan, Jasmita Dass, Seema Tyagi, Manoranjan Mahapatra & Tulika Seth. (2021) Venetoclax and azacitidine (VenAZA) combination therapy in young unfit patients with AML: a perspective from a developing country. Leukemia & Lymphoma 62:6, pages 1514-1517.
Read now

Articles from other publishers (23)

Ryujiro Hara, Shinichiro Machida, Norisato Hashimoto, Daisuke Ogiya, Hidetsugu Kawai, Shohei Kawakami, Sawako Shiraiwa, Makoto Onizuka, Yoshiaki Ogawa, Hiroshi Kawada & Kiyoshi Ando. (2023) Impact of previous anthracycline therapy in patients with acute myeloid leukemia receiving venetoclax. International Journal of Hematology 118:6, pages 711-717.
Crossref
Yan‐Ling Yang, Zhou‐Yi Qian, Yang Zhao, Xiang‐Long Chen, Qiong‐Ye Huang, Yu‐Jiao Guo, Lu‐Ning Sun & Yong‐Qing Wang. (2023) LC–MS/MS methods for determination of venetoclax in human plasma and cerebrospinal fluid. Biomedical Chromatography 37:12.
Crossref
C. Petit, C. Saillard, B. Mohty, Y. Hicheri, F. Villetard, V. Maisano, A. Charbonnier, J. Rey, E. D‘Incan, C. Rouzaud, V. Gelsi‐Boyer, A. Murati, A. C. Lhoumeau, A. Ittel, M. J. Mozziconacci, A. S. Alary, M.‐A. Hospital, N. Vey & S. Garciaz. (2023) Azacitidine–venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients. European Journal of Haematology.
Crossref
Dongmei Wang, Tao Sun, Yuan Xia, Zhe Zhao, Xue Sheng, Shuying Li, Yuechan Ma, Mingying Li, Xiuhua Su, Fan Zhang, Peng Li, Daoxin Ma, Jingjing Ye, Fei Lu & Chunyan Ji. (2023) Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation. Nature Communications 14:1.
Crossref
Lejiao Jia, Huatian Yang, Dandan Zheng, Jingjing Ye, Qian Zhou, Genjv Li, Ying Zhou, Xinyu Yang, Jinting Liu, Feng Ye, Yuliang Song, Daoxin Ma & Chunyan Ji. (2023) Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia. ACS Applied Materials & Interfaces 15:23, pages 27624-27637.
Crossref
Elisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, Elisabetta Petracci, Chiara Zingaretti, Calogero Vetro, Maria Paola Martelli, Patrizia Zappasodi, Nicola Di Renzo, Susanna Gallo, Ernesta Audisio, Davide Griguolo, Claudio Cerchione, Carmine Selleri, Daniele Mattei, Massimo Bernardi, Monica Fumagalli, Giuliana Rizzuto, Luca Facchini, Claudia Maria Basilico, Ilenia Manfra, Erika Borlenghi, Roberto Cairoli, Prassede Salutari, Michele Gottardi, Alfredo Molteni, Vincenza Martini, Monia Lunghi, Luana Fianchi, Daniela Cilloni, Francesco Lanza, Elisabetta Abruzzese, Nicola Cascavilla, Flavia Rivellini, Felicetto Ferrara, Luca Maurillo, Jacopo Nanni, Alessandra Romano, Valeria Cardinali, Federica Gigli, Elisa Roncoroni, Vincenzo Federico, Giovanni Marconi, Roberta Volpi, Mariarita Sciumè, Corrado Tarella, Giuseppe Rossi & Giovanni Martinelli. (2023) AVALON: The Italian cohort study on real‐life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia. Cancer 129:7, pages 992-1004.
Crossref
Romeo G. Mihăilă. (2023) Venetoclax in Acute Myeloid Leukemia. Recent Patents on Anti-Cancer Drug Discovery 18:1, pages 11-28.
Crossref
Hugo Gonzalez, Alice Marceau-Renaut, Marc Spentchian, Maen Hassoun & Geoffroy Guignedoux. (2022) Leon's helmet. Haematologica 108:5, pages 1450-1451.
Crossref
Avraham Frisch, Shlomzion Aumann, Tsila Zuckerman, Ronit Leiba, Noa Gross Even-Zohar, Moshe E. Gatt, Vladimir Vainstein, Adir Shaulov, Alexander Gural, Eran Zimran, Yaniv Zohar, Yishai Ofran & Boaz Nachmias. (2022) Re-induction versus salvage for D14-resiudal acute myeloid leukemia: A retrospective multi-center study. Leukemia Research 119, pages 106902.
Crossref
Piotr Obszański, Anna Kozłowska, Jakub Wańcowiat, Julia Twardowska, Monika Lejman & Joanna Zawitkowska. (2022) Molecular-Targeted Therapy of Pediatric Acute Myeloid Leukemia. Molecules 27:12, pages 3911.
Crossref
Sylvain Garciaz, Marie-Anne Hospital, Anne-Sophie Alary, Colombe Saillard, Yosr Hicheri, Bilal Mohty, Jérôme Rey, Evelyne D’Incan, Aude Charbonnier, Ferdinand Villetard, Valerio Maisano, Laura Lombardi, Antoine Ittel, Marie-Joelle Mozziconacci, Véronique Gelsi-Boyer & Norbert Vey. (2022) Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients. Cancers 14:8, pages 2025.
Crossref
Jorge Labrador, Miriam Saiz-Rodríguez, Dunia de Miguel, Almudena de Laiglesia, Carlos Rodríguez-Medina, María Belén Vidriales, Manuel Pérez-Encinas, María José Sánchez-Sánchez, Rebeca Cuello, Alicia Roldán-Pérez, Susana Vives, Gonzalo Benzo-Callejo, Mercedes Colorado, María García-Fortes, María José Sayas, Carmen Olivier, Isabel Recio, Diego Conde-Royo, Álvaro Bienert-García, María Vahi, Carmen Muñoz-García, Cristina Seri-Merino, Mar Tormo, Ferran Vall-llovera, María-Ángeles Foncillas, David Martínez-Cuadrón, Miguel Ángel Sanz & Pau Montesinos. (2022) Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience. Cancers 14:7, pages 1734.
Crossref
Giulia Ciotti, Giovanni Marconi & Giovanni Martinelli. (2022) Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia. Frontiers in Oncology 11.
Crossref
Jane L. Liesveld, Andrea Baran, Mitra Azadniv, Haley Misch, Katherine Nedrow, Michael Becker, Kah Poh Loh, Kristen M. O’Dwyer & Jason H. Mendler. (2022) A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia. Leukemia Research 112, pages 106749.
Crossref
Peng Zhao, Ming Ni, Dan Ma, Qin Fang, Yan Zhang, Yanju Li, Yi Huang, Ying Chen, Xiao Chai, Yun Zhan, Yan Li, Qian Kang, Mei Zhao, Min Liu, Fengqi Zhang, Shisi Huang, Shuangshuang Wen, Bo Deng & Jishi Wang. (2021) Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation. Annals of Hematology 101:1, pages 119-130.
Crossref
Serena Brancati, Lucia Gozzo, Giovanni Luca Romano, Calogero Vetro, Ilaria Dulcamare, Cinzia Maugeri, Marina Parisi, Laura Longo, Daniela Cristina Vitale, Francesco Di Raimondo & Filippo Drago. (2021) Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?. Cancers 14:1, pages 22.
Crossref
Andrius Zucenka, Vilmante Vaitekenaite, Kazimieras Maneikis, Linas Davainis, Regina Pileckyte, Igoris Trociukas, Valdas Peceliunas, Tadas Zvirblis, Vytautas Staras & Laimonas Griskevicius. (2021) Venetoclax-based salvage therapy followed by Venetoclax and DLI maintenance vs. FLAG-Ida for relapsed or refractory acute myeloid leukemia after allogeneic stem cell transplantation. Bone Marrow Transplantation 56:11, pages 2804-2812.
Crossref
Anna Geueke, Giada Mantellato, Florian Kuester, Peter Schettina, Melanie Nelles, Jens Michael Seeger, Hamid Kashkar & Catherin Niemann. (2021) The anti‐apoptotic Bcl‐2 protein regulates hair follicle stem cell function. EMBO reports 22:10.
Crossref
Matteo Piccini, Sofia Pilerci, Marta Merlini, Pietro Grieco, Barbara Scappini, Sara Bencini, Benedetta Peruzzi, Roberto Caporale, Leonardo Signori, Fabiana Pancani, Alessandro Maria Vannucchi & Giacomo Gianfaldoni. (2021) Venetoclax-Based Regimens for Relapsed/Refractory Acute Myeloid Leukemia in a Real-Life Setting: A Retrospective Single-Center Experience. Journal of Clinical Medicine 10:8, pages 1684.
Crossref
Jonathan Feld, Douglas Tremblay, Mikaela Dougherty, Tina Czaplinska, Gillian Sanchez, Claudia Brady, Marina Kremyanskaya, Michal Bar-Natan, Alla Keyzner, Bridget K. Marcellino, Janice Gabrilove, Shyamala C. Navada, Lewis R. Silverman, Siraj M. El JamalJohn Mascarenhas & Alan H. Shih. (2021) Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies. HemaSphere 5:4, pages e549.
Crossref
Maximilian Stahl, Kamal Menghrajani, Andriy Derkach, Alexander Chan, Wenbin Xiao, Jacob Glass, Amber C. KingAnthony F. Daniyan, Christopher Famulare, Bernadette M. CuelloTroy Z. HorvatOmar Abdel-Wahab, Ross L. Levine, Aaron D. Viny, Eytan M. Stein, Sheng F. Cai, Mikhail RoshalMartin S. Tallman & Aaron D. Goldberg. (2021) Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Advances 5:5, pages 1552-1564.
Crossref
Andrius Zucenka, Regina Pileckyte, Igoris Trociukas, Valdas Peceliunas, Vilmante Vaitekenaite, Kazimieras Maneikis, Linas Davainis, Tadas Zvirblis, Mindaugas Stoskus, Egle Gineikiene, Rimvydas Norvilas, Vaidas Dirse, Agne Surauciute, Emile Zucenkiene & Laimonas Griskevicius. (2020) Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies. European Journal of Haematology 106:1, pages 105-113.
Crossref
Naseema Gangat & Ayalew Tefferi. (2020) Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points. Blood Cancer Journal 10:11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.